Small molecule · Inhibitor of methionine adenosyltransferase II alpha (MAT2A) · developed by BeOne Medicines
BG-89894 is an orally bioavailable inhibitor of MAT2A, the metabolic enzyme that produces S-adenosyl-L-methionine, the main methyl donor for cellular transmethylation. It is being studied in advanced solid tumors, including MTAP-deleted cancers that depend heavily on SAM synthesis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06589596 | Phase 1 | Advanced Solid Tumor | Recruiting | ONC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid Tumor
Updated Oct 25, 2026. Something wrong or missing? Report it on the ONC page.
See ONC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ONC catalysts and pipeline →